[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479985":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":20,"armGroups":21,"interventions":27,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":64,"collaborators":16,"id":66,"slug":16,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":16,"enrollmentInfo":75,"targetDuration":78,"studyType":79,"phases":16,"briefSummary":80,"conditions":81,"keywords":16,"overallStatus":46,"whyStopped":16,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Sir Mortimer B. Davis - Jewish General Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"To validate the sensitivity of Telo Genomics assay (measurement tool) to detect MRD (measurement expressed in the number of plasma cells per 100000 cells) and establish the clinical utility of TELO - DMRD for MRD enumeration","Assess the possibility to perform TELO-DMRD on bone marrow aspirate samples vs peripheral blood\n\nValidate TELO-DMRD results with ClonoSeq, as an IMWG recognized MRD assessment method (other IMWG recognized methodologies can be also employed)","Approximately 5 years",{"measure":14,"description":15,"timeFrame":12},"To assess the utility of TeloView® technology genomic profiling (measurement tool) to stratify post-transplant MM patients into relapse risk groups (dichotomous measure of high or low) by analyzing the residual MRD plasma cells","o A longitudinal study including transplant eligible patients. Patients to be followed for 6 time points over 24 months at: At point of diagnosis (marrow aspirate \\& peripheral blood), 4m post induction (peripheral blood), 3m Post-transplant (peripheral blood), at 12m Post-transplant (peripheral blood), 18m Post-transplant (peripheral blood) \\& 24m Post-transplant (peripheral blood), and at point of relapse for patients who will relapse during the follow up time (marrow aspirate \\& peripheral blood). Of note, an additional marrow aspirate may be performed if the patient agrees at the time they attain a complete remission, to confirm this status",null,{"allocation":16,"interventionModel":16,"interventionModelDescription":16,"primaryPurpose":16,"observationalModel":18,"timePerspective":19,"maskingInfo":16},"COHORT","PROSPECTIVE","Participant having confirmed Multiple Myeloma diagnosis will be enrolled in this study.",[22],{"label":23,"type":16,"description":24,"interventionNames":25},"MRD level group","Participants will be defined as diagnosed with multiple myeloma",[26],"Diagnostic Test: Standard of care",[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":16},"DIAGNOSTIC_TEST","Standard of care","Participants will not receive any intervention in this study. Participants will receive standard of care therapy",[23],[34],{"name":35,"affiliation":5,"role":36},"Rayan Kaedbey","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":16,"email":42},"Rayan Kaedbey, MD FRCPC","CONTACT","514-340-8222","rayan.kaedbey.med@ssss.gouv.qc.ca",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Jewish General Hospital","RECRUITING","Montreal","Quebec","H3T 1E2","Canada","CA",{"type":53,"coordinates":54},"Point",[55,56],-73.58781,45.50884,{"lat":56,"lon":55},[59],{"name":60,"role":40,"phone":61,"phoneExt":62,"email":63},"Rayan Kaedbey, MD","514 340 8222","28799","rayan.kaedbey@mcgill.ca",{"type":36,"investigatorFullName":35,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"Principal Investigator","100479985",false,"NCT05530096","Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD","Detect and Profile Multiple Myeloma Measurable Residual Disease (MRD )Prognostics for Monitoring Post-transplant Multiple Myeloma (MM) Patients Receiving Maintenance Therapy.","TELO - DMRD","Inclusion Criteria:\n\n* Confirmed MM diagnosis\n* Transplant eligible patients in a first remission\n* Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)\n* Availability of deidentified patient's demographic and clinical follow up data\n* Receiving standard of care treatment\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Failure to meet inclusion criteria","ALL","18 Years",{"count":76,"type":77},70,"ESTIMATED","24 Months","OBSERVATIONAL","The purpose :\n\nDetect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.",[82],"Multiple Myeloma","2025-03-30",{"date":85,"type":86},"2025-04-03","ACTUAL",{"date":88,"type":86},"2024-05-01",{"date":90,"type":77},"2028-09",{"name":5,"class":6},1]